Canon Medical Systems USA Presents Its First-Ever U.S. Mobile Truck Tour with the Launch of Canon Across America

A Mobile Roadshow Designed to Showcase the Future of Medical Imaging

Canon Medical Systems USA, Inc. (CMSU), a global leader in innovative diagnostic imaging technology, is proud to announce its first-ever U.S. mobile tour, Canon Across America, March 24th through December 2, 2022.

Canon Medical Systems USA will bring its state-of-the-art AI medical devices to hospitals and local healthcare providers in a unique hands-on experience to create stronger community engagement throughout the year.

CMSU’s 50-city mobile tour kicks off in its Tustin, CA headquarters and will travel across the country. The Canon Across America mobile truck tour aims to provide healthcare professionals and hospitals across the U.S. the opportunity to connect with Canon’s innovative solution-focused portfolios at a hands-on level by providing a holistic 360-degree view of their solutions. In addition, Canon will provide live demos, supportive conversations with Canon’s industry experts, and an opportunity to experience the benefits Canon’s platforms offer at their convenience.

“Providing in-person experiences with current and new customers is key for us as a company. It’s a vital opportunity to connect, ask pressing questions in a face-to-face setting, and to learn more about better servicing their needs,” said David Hashimoto, Vice President of Marketing and Sales Strategy. “We’re allowing unprecedented access to our technologies to better guide healthcare professionals with the essential information needed to make important decisions about their patients and business.”

Yuji Hamada, President and CEO of Canon Medical Systems USA, agrees. “Canon’s 50-city tour is a unique opportunity for healthcare professionals to gain access to personalized demos. The next generation of medical imaging allows us to provide our customers flexible visits with Canon’s reps and to focus on key areas of interest important to them. We look forward to this year-long journey of meeting our customers, friends, and colleagues and showcasing the very best that Canon has to offer.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”